Revance Therapeutics | RVNC - Cost Of Sales

Revance Therapeutics reported $23.52M in Cost of Sales for its fourth fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Cost Of Sales Change
Abbvie ABBV:US USD 4.17B 57M
ALKERMES ALKS:US USD 53.96M 3.34M
Bristol Myers Squibb BMY:US USD 2.52B 167M
Cara Therapeutics CARA:US USD 2.13M 925K
Coherus Biosciences CHRS:US USD 14.2M 21.03M
Eli Lilly And LLY:US USD 1.55B 31M
Endo International Ordinary Shares ENDP:US USD 176.86M 1.06M
Horizon Pharma HZNP:US USD 240.79M 6.65M
JAZZ PHA JAZZ:US USD 167.36M 33.7M
Johnson & Johnson JNJ:US USD 7.76B 29M
Merk MRK:US USD 3.36B 519M
Neurocrine Biosciences NBIX:US USD 7.7M 1.6M
Pacira Pharmaceuticals PCRX:US USD 61.92M 11.24M
Procter & Gamble PG:US USD 10.9B 51M
Revance Therapeutics RVNC:US USD 23.52M 12.78M
Supernus Pharmaceuticals SUPN:US USD 22.95M 2.92M
Teva Pharmaceutical Industries TEVA:US USD 1.78B 101M